Brielle Benyon

"Certainly germline and somatic is recommended for all mCRPC patients to detect HR gene mutations, and consider options for PARP inhibitors,” says Neal Shore, MD, FACS.

“Belzutifan demonstrated a significant improvement in PFS with a hazard ratio of .75, and a significant P value. Similar findings were noted at the second interim analysis with a hazard ratio of .74,” says Laurence Albiges, MD, PhD.

Overall survival outcomes were similar to those treated with 177Lu-PSMA-617 more than 6 months after radium-223 treatment, according to findings from the RALU study.

“These results further support the use of lenvatinib plus pembrolizumab as a standard-of-care first-line treatments for patients with [advanced] RCC,” the authors wrote.

Treatment with tivozanib was associated with a fivefold increased likelihood of experiencing long-term progression-free survival compared to treatment with sorafenib.

First-line tivozanib in patients with metastatic renal cell carcinoma was reported to be safe, tolerable, and capable of producing similar clinical activity as other tyrosine kinase inhibitors used in this setting.

The retrospective cohort study assessed outcomes in patients with advanced renal cell carcinoma who received cabozantinib or axitinib in the second-line setting or beyond.

The novel agent eganelisib led to higher response rates with nivolumab in PD-L1–low patients with metastatic urothelial carcinoma.